Ann: Mesoblast Type A Meeting with FDA, page-230

"Oh they certainly will when MSB reaches 'sustainable commercialisation'.
An authoritative-sounding term, which neatly fails to mention the risk vs reward analysis necessary in evaluation any biotech."

Only authoritative-sounding to those who fail to comprehend the concept, but for a great many investors, it represents a belts-and-braces approach to risk management.

On that important topic of managing risk, somewhat presciently, the phrase "self sustaining commercialisation" was first posted on these threads several years ago, ahead of the stock subsequently losing something like 90% of its value.

.